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Testing for SARS-CoV-2 in resource-poor settings remains a considerable challenge. Gold standard nucleic
acid tests are expensive and depend on availability of expensive equipment and highly trained laboratory
staff. More affordable and easier rapid antigen tests are an attractive alternative. This study assessed field
performance of such a test in western Kenya. We conducted a prospective multi-facility field evaluation
study of NowCheck COVID-19 Ag-RDT compared to gold standard PCR. Two pairs of oropharyngeal and naso-
pharyngeal swabs were collected for comparative analysis. With 997 enrolled participants the Ag-RDT had a
sensitivity 71.5% (63.2-78.6) and specificity of 97.5% (96.2-98.5) at cycle threshold value <40. Highest sensi-
tivity of 87.7% (77.2-94.5) was observed in samples with cycle threshold values ≤30. NowCheck COVID-19
Ag-RDT performed well at multiple healthcare facilities in an African field setting. Operational specificity
and sensitivity were close to WHO-recommended thresholds.




Point of care testing
Developing countryc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Background
Since it was first described in December 2019 in Wuhan, Hubei
Province in China, the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has
caused a significant global public health problem(Wang et al., 2020).
As of 26 November 2021 , SARS-COV-2 had resulted in 259,502,031
infections resulting in 5,183,003 deaths in over 220 countries
(WHO, 2021). Preventing the spread of SARS-COV-2 is a global public
health priority requiring multiple interventions such as social dis-
tancing, hand hygiene, infection protection devices, vaccination,
timely and accurate diagnosis, and treatment of the sick (Botti-
Lodovico et al., 2021; Gates, 2020).
Reverse transcriptase-polymerase chain reaction (RT-PCR) of
nasal/oropharyngeal samples is the gold standard diagnostic method
for SARS-CoV-2 (Ishige et al., 2020). Though RT-PCR has high sensitiv-
ity, it requires a robust infrastructure, well-trained staff, an elaboratesupply chain to support testing services, and it comes at a high cost
(Y€uce et al., 2021). In many low and middle-income
countries (LMICs), there are significant gaps to support RT-PCR test-
ing, resulting in limited access to testing. Although a typical RT-PCR
assay takes an average of 4 to 6 hours, in most countries, the time to
get results is much longer due to logistics, inefficient reporting sys-
tems and lack of digital data management (New guidance to expand
rapid antigen testing for COVID-19 response in Africa released, 2020;
Mulu et al., 2021). Furthermore, access is much more limited in hard-
to-reach communities, making controlling the pandemic a problem-
atic task. With low vaccination rates not exceeding 2% in Africa and
across many low-and middle-income countries, testing remains a
crucial pillar in the fight against SARS-COV-2 (Nachega et al., 2021;
Sah et al., 2021). In these settings, point of care (POCT) Ag-RDTs pro-
vides a practical alternative to RT-PCR based testing.
Although Ag-RDTs may not fully replace RT-PCR testing, they offer
an easy-to-use POCT method. Moreover, Ag-RDTs can easily be scaled
to community settings since they do not require any equipment or
well-trained laboratory staff. The quick turnaround time of 15 to 30
minutes helps in faster triage, rapid mass testing, correct patient
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(Rottenstreich et al., 2021). The low cost per test and ease of use of
Ag-RDTs makes them a suitable public health tool to widely scale-up
testing in LMICs even in remote communities and in high transmis-
sion zones (Ricks et al., 2021; Rottenstreich et al., 2021).
The World Health Organization (WHO) recommends using anti-
gen test kits with a sensitivity of at least 80% and specificity of greater
than 97% compared to the gold standard RT-PCR (WHO, 2020). In
these settings, such Ag-RDTs provides a decent alternative to RT-PCR,
hence the rapid increase in production of several such kits in the mar-
ket within a short period. As of July 25, 2021, less than 20 months
since the COVID-19 pandemic started, 176 listed antigen kits on the
Foundation for Innovative New Diagnostics, (a global alliance for
diagnostics that seeks to prioritize, partner, develop, evaluate, and
support the equitable implementation of diagnostic tests) website
(FIND, n.d.).
Although various kit manufacturers report the performance of
their diagnostic kits, their operational performance can vary when
subjected to the field or real-world conditions. Diagnostic perfor-
mance of most Ag-RDTs in the market are yet to be adequately evalu-
ated in field situations in LMIC settings. Moreover, most regulators
carry out only limited, laboratory-based Ag-RDT evaluations before
granting emergency use authorizations for use (Prince-Guerra et al.,
2021). This study aimed at an in-depth evaluation of the field perfor-
mance of BioNote NowCheck COVID-19 Ag-RDT among Kenyans sus-
pected to have COVID-19 attending four health facilities in Kisumu
County in western Kenya.
2. Materials and methods
2.1. Study design and oversight
We conducted a cross-sectional, prospective diagnostic evaluation
study comparing the field-based operational performance of the
NowCheck SARS-CoV-2 Ag-RDT against the gold standard RT-PCR.
Four health facilities in Kisumu County participated, consisting of pri-
vate hospitals, public hospitals, and faith-based hospitals, all of which
were part of a public-private partnership in response to the SARS-
CoV-2 pandemic in Kisumu dubbed "COVID-Dx". We obtained
research and ethical approval from Jaramogi Oginga Odinga Teaching
& Referral Hospital under IERC/JOOTRH/334/20 and Research License
from National Commission for Science, Technology, and Innovation,
license number BAHAMAS ABS/P/20/7959. We obtained informed
consent for all eligible adults and assent and parental consent for eli-
gible minors below 18 years. All study procedures were carried out
according to ethical principles of the Helsinki Declaration of 1964
and good clinical practices. All study personnel were appropriately
trained on infection prevention control using the Kenyan Ministry of
Health guidelines and provided with personal protective equipment.
2.2. Sample collection
Trained laboratory technicians collected paired nasopharyngeal
and oropharyngeal samples from eligible participants attending four
healthcare facilities in Kisumu County. Eligible participants met the
Ministry of Health COVID-19 case definition and provided informed
consent before sample collection was undertaken. Pre- and post-test
counselling services were provided as additional support for partici-
pants.
2.3. Antigen testing
The NowCheck SARS-CoV-2 Ag test is a rapid antigen chro-
matographic immunoassay for the qualitative detection of N protein
of SARS-CoV-2 antigens (NowCheck COVID-19 Ag, n.d.). Trained
health workers carried out the testing procedure according to themanufacturer's specifications. The results were provided to patients
within 15 to 30 minutes of testing while awaiting final RT-PCR results
within 24 to 48 hours. The results were digitally captured onto a tab-
let/smartphone application (digitized Kenyan COVID-19 Case Investi-
gation Form) and stored in a safe cloud server as described here
(Smith et al., 2019), together with general information on the
patients (such as age, gender and occupation). Results release, patient
care and follow up was performed according to the Kenya Ministry of
Health guidelines (Ministry of Health, 2020).
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR testing was centrally performed at Kenya Medical
Research Institute. SARS-CoV-2 viral ribonucleic acid (RNA) extrac-
tion from the paired nasopharyngeal and oropharyngeal samples was
manually done using MagMAXTM Viral RNA Isolation Kit (Thermo
Fisher Scientific, MA). Post-RNA extraction, real-time SARS-CoV-2
PCR was carried out using TaqPathTM 19 kit (Thermo Fisher Scientific,
MA). Three primer sets specific to different SARS-CoV-2 genomic
regions (ORF1ab, N gene, S gene) were used for the RT-PCR reaction.
Probes for bacteriophage MS2 were added as an RNA control to verify
the efficacy of the sample preparation and the absence of inhibitors
in the RT-PCR reaction. The assays were set up on the 7500 Fast Real-
Time PCR Instrument (Applied Biosystems, Thermo Fisher Scientific,
MA). A 5 ml template RNA from each sample's nucleic acid was used
with 20ml of the PCR master-mix.
The following thermocycling conditions were employed; 2
minutes at 25°C incubation, 10 minutes at 53°C for reverse tran-
scription, 2 minutes at 95°C for enzyme activation and 40 cycles of
3 seconds at 95°C and 30 seconds at 60°C. Samples having exponen-
tial growth curve and Ct<40 in at least two SARS-CoV-2 targets
were considered positive, while those with Ct values in only one tar-
get were inconclusive. Assays with all targets, including MS2 nega-
tive, were deemed invalid. All invalid and inconclusive assays were
repeated. All test procedures were performed according to manufac-
turer-prescribed protocols. The antigen test results were compared
with gold-standard RT-PCR results and used to compute kit field
performance specifications. Table 1 below provides the breakdown
of paired antigen and PCR testing across the four facilities marked A
to D.
2.5. Statistical analysis
Analyses were performed using STATA-15 (StataCorp LLC, TX) and
Microsoft Excel (Microsoft, Redmond, WA). We used descriptive sta-
tistics to describe the general information of study participants. Con-
tinuous data were summarized and presented in means, standard
deviation (SD), median, and range as applicable. Categorical data
were summarized in percentages, and a significance value of 0.05 in
statistic tests was considered. Ag-RDT sensitivity, specificity, positive
likelihood ratio, negative likelihood ratio, positive predictive value,
negative predictive value, and accuracy were calculated using Med-
Calc online software calculator (Schoonjans, n.d.), grouped according
to Ct values using the following cut-offs: 25, 30, 35 and 40
3. Results
3.1. Demographic characteristics
From 28 December 2020 and 31 March 2021, 997 eligible partici-
pants were enrolled in the study across four health facilities. The
median age was 37 years (interquartile range, 28−49 years). Their
demographic characteristics are summarized in Table 1. The distribu-
tion of antigen and RT-PCR testing across the four participating
health facilities in Kisumu County are summarized in Table 2 below.
Table 1
Demographic characteristics of study participants.





Informal workers 367(36.8) 33.86−39.86
Formal workers (non-healthcare) 276(27.7) 24.98−30.55
Students 163(16.4) 14.17−18.78
Healthcare workers 124(12.4) 10.52−14.64
Unemployed 42(4.2) 3.12−5.65




Sore throat 596(13.0) 12.07−14.03
General weakness 548(12.0) 11.06−12.94
Nausea/vomiting 508(11.1) 10.22−12.04
History of fever/chills 426(9.3) 8.50−10.18




Shortness of breath 80(1.8) 1.40−2.17
Other 8(0.2) 0.08−0.34
Asymptomatic 3(0.1) 0.02−0.20
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When compared against RT-PCR as the gold standard, the kit sen-
sitivity and specificity showed variable performance across varying
Ct values (Table 3). The lowest sensitivity, 71.5% (63.2−78.6), was
reported at Ct value <40, while the lowest specificity of 89.5% (87.4
−91.4) was noted at the lowest Ct values. We observed the best Ag-
RDT performance when the Ct values were ≤35 with a sensitivity of
84.5% (76.00%−90.9%) and specificity of 95.3% (93.7−96.6). At this
cut-off, the diagnostic accuracy was 94.2% (92.5−95.6). The highest
sensitivity of 87.7% (77.2−94.5) was observed in samples with Ct val-
ues ≤30, corresponding with samples with higher viral loads. At Ct
value <40, kit sensitivity dropped to 71.5% (63.2−78.6) with a speci-
ficity matching that of RT-PCT at 97.5% (96.2−98.5).Table 2
Distribution of antigen and PCR testing across facilities in Kisumu County.
Facility Ag-RDT results per Facility
Negative Positive Total RDT
Facility A 106 45 151
Facility B 644 72 716
Facility C 71 10 81
Facility D 47 2 49
Totals 868 129 997
Table 3
Performance characteristics of NowCheck COVID-19 Ag-RDT across grouped PCR Ct values.
Ct ≤25 Ct ≤30
Sensitivity 87.5% (71.0−96.5) 87.7% (77
Specificity 89.5% (87.4−91.4) 92.3% (90
Positive Likelihood Ratio 8.4(6.7−10.5) 11.4(8.9−
Negative Likelihood Ratio 0.14(0.1−0.4) 0.13(0.1−
Positive Predictive Value 21.7% (18.1−25.8) 44.2% (38
Negative Predictive Value 99.5% (98.9−99.8) 99.1% (98
Accuracy 89.5% (87.5−91.3) 91.9% (904. Discussion
Testing is essential for controlling SARS-COV-2 infection, allowing
early identification and isolation of cases to slow down transmission,
and providing timely clinical management to those affected and pro-
tecting health systems operations through triaging at admissions
(Taleghani and Taghipour, 2021). In most LMICs, access to RT-PCR
testing capacity is limited to a few specialized centres resulting in sig-
nificant delays in testing (Kobia and Gitaka, 2020; Mina et al., 2020).
Ag-RDTs presents a suitable testing method with several advantages.
These include low cost per test, availability as point-of-care, easy to
use, does not require electricity, specialized skills or special equip-
ment. The lower cost per test and ease of rolling out to remote com-
munities may offer opportunities to rapidly scale up to meet the high
demand for testing, contributing to effective control of the COVID-19
pandemic(Peeling et al., 2021; WHO, 2020).
In its preliminary guidance on using SARS-CoV-2 rapid antigen
kits, the WHO recommends using kits with a sensitivity of ≥ 80% and
specificity greater than 97% WHO, 2020). In this study, we sought to
evaluate the field performance of the NowCheck SARS-CoV-2 antigen
kit in a field context, comparing it with the manufacturer's reported
sensitivity and specificity of 89.2% and 97.3%, respectively. In this
field evaluation, the BioNote NowCheck kit shows an excellent sensi-
tivity of 84.5% (76.0%−90.7%) and specificity 95.30% (93.7%−96.6%)
when Ct value ≤35 was used. The sensitivity dropped to 71.5% (63.2
−78.6) and specificity increased to 97.5% (96.2−98.5) when using a Ct
value of ≤40. The highest sensitivity was in samples with a Ct value
≤30, corresponding to a higher viral load. At Ct values ≤30, the sensi-
tivity was 87.7% (77.2−94.5) and specificity at 92.3% (90.4−93.9).
Studies from around the world evaluating various rapid diagnostic
antigen kits show mixed findings (Jonathan et al., 2020). Reported
sensitivities vary from as low as 30.2% for Coris COVID-19 Ag Respi-
Strip(Scohy et al., 2020) to 64% for the Alltest lateral flow immunoas-
say (Perez-García et al., 2020) to kits with reported sensitivities
higher than 80% such as Orient Gene, Deepblue, Abbott and Innova
SARS-CoV-2 Antigen Rapid(Peto et al., 2021). In a field evaluation
study by Eliseo et al., similar to our study in a primary health centre,
the Panbio Ag-RDT kit showed a sensitivity of 79.6% and specificity of
100%(Torres et al., 2021). Again, in a similar field evaluation of Stan-
dard Q Ag-RDT in Uganda, Nalumansi et al. (Nalumansi et al., 2021)
noted a less than optimal performance with a sensitivity of 70% and
specificity of 92%. The authors noted better performance at lower CtSARS CoV 2 RT-PCR






Ct ≤35 Ct ≤40
.2−94.5) 84.5% (76.0 − 90.85) 71.5% (63.2−78.6)
.4−93.9) 95.30% (93.7 − 96.59) 97.5% (96.2−98.5)
14.4) 17.98 (13.2 to 24.4) 28.81(18.7−44.5)
0.3) 0.16 (0.1 − 0.3) 0.29(0.2−0.4)
.4−50.2) 67.4% (60.4 −73.79) 83.7% (76.9−88.1)
.3−99.5) 98.16% (97.1% − 98.8) 95.1% (93.7−96.1)
.1−93.6) 94.18% (92.5 to 95.6) 93.6% (91.9−95.0)
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confirmed by Nahal et al. (Eshghifar et al., 2021), who evaluated
seven different rapid antigen kits and noted better performance at
higher viral load, with an optimal Ct value of ≤25.
To our knowledge, this is the first study in Kenya to extensively
evaluate the field performance of an affordable COVID-19 Ag-RDT kit.
The Ag-RDT kit showed excellent sensitivity and specificity compared
to the gold standard, despite the challenges of the real-world envi-
ronment. Such challenges included variability in sample collection
practices among laboratory technicians across different healthcare
facilities. Rapid turnover of healthcare staff requiring regular retrain-
ing. Growing stigma and fear due to curfews, lockdowns and strin-
gent quarantine measures contributed to laboratory staff hesitation
to collect samples (to the level of requesting 'danger allowances').
Shipment of samples to the central laboratory through motorbikes
experienced cooling challenges. Patients became increasingly critical
to getting tested, given the limited perspectives offered when testing
positive. Stock-outs of reagents and kits for RT-PCR occurred, as well
as (temporary) breakdowns of crucial laboratory equipment.
In general, the Ag-RDT kit proved easy to use, requiring minimal
training time. Patients' discomfort during sample taking was report-
edly minimal, and they appreciated an earlier (preliminary) COVID-
19 test result. Patients and health workers considered the immediate
availability of pre-and post-test counselling services of good value in
nudging subsequent patient behaviour, including quarantining, sup-
port of contact tracing and hospitalization of those in need. This study
provides a proof of concept that rapid antigen kits can easily be rolled
out to the community level to support the quick point-of-care diag-
nosis that allows rapid patient triage, quarantining and hospital
placement. In areas with limited access to RT-PCR testing and high
patient flow, Ag-RDTs can be scaled up to remote locations, support
quick turnaround times for test results with minimal training
requirements. Rapid testing can help quick and effective contact trac-
ing at the POCT, supporting efforts to contain SARS CoV-2 spread
within the community.
Though helpful, the limitations of these kits should be noted by the
users. Some studies have suggested low sensitivity in screening
asymptomatic patients (Eshghifar et al., 2021; Pe~na et al., 2021;
Torres et al., 2021). Various authors have cited lower sensitivity in
patients with low viral load (high Ct values on RT-PCR); hence RT-PCR
testing should continue to be offered where clinical suspicion is high
(Ebrahimi et al., 2021; Nalumansi et al., 2021; Peeling et al., 2021).
The users should follow manufacturers laid down testing procedures
to avoid potentially misleading false-negative or false-positive results.5. Conclusion
In this study, we carried out a field evaluation of a rapid antigen
test for COVID-19 across four healthcare facilities in western Kenya.
The performance of the kit almost met theWHO cut-off specifications
in detecting COVID-19 when compared to the current gold standard
method. We note that The BioNote NowCheck rapid antigen test is a
realistic testing option for usage in Africa in the fight against the
COVID-19 pandemic.
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